Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada ; volume:20 ; number:1 ; day:15 ; month:4 ; year:2020 ; pages:1-10 ; date:12.2020
BMC cancer ; 20, Heft 1 (15.4.2020), 1-10, 12.2020
- Creator
-
Dai, Wei Fang
Beca, Jaclyn M.
Croxford, Ruth
Isaranawatchai, Wanrudee
Menjak, Ines B.
Petrella, Teresa M.
Mittmann, Nicole
Earle, Craig C.
Gavura, Scott
Hanna, Timothy P.
Chan, Kelvin K.W
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-020-06798-1
- URN
-
urn:nbn:de:101:1-2020062814063733572884
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:51 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Dai, Wei Fang
- Beca, Jaclyn M.
- Croxford, Ruth
- Isaranawatchai, Wanrudee
- Menjak, Ines B.
- Petrella, Teresa M.
- Mittmann, Nicole
- Earle, Craig C.
- Gavura, Scott
- Hanna, Timothy P.
- Chan, Kelvin K.W
- SpringerLink (Online service)
Other Objects (12)
A Dramatic Response to Second-Line Nivolumab and Ipilimumab in BRAF-V600-Mutated Metastatic Melanoma
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
Ipilimumab in patients with melanoma and autoimmune disease
Acute visual loss after ipilimumab treatment for metastatic melanoma
Biomarkers on melanoma patient T Cells associated with ipilimumab treatment
Bilateral neuroretinitis and anterior uveitis following ipilimumab treatment for metastatic melanoma
MISIPI study: Melanoma ImmunoScore evaluation in patients treated with IPIlimumab
Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab
Large granular lymphocytosis with severe neutropenia following ipilimumab therapy for metastatic melanoma
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian ipilimumab expanded access programme (EAP)
Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy
A Dramatic Response to Second-Line Nivolumab and Ipilimumab in BRAF-V600-Mutated Metastatic Melanoma
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
Ipilimumab in patients with melanoma and autoimmune disease
Acute visual loss after ipilimumab treatment for metastatic melanoma
Biomarkers on melanoma patient T Cells associated with ipilimumab treatment
Bilateral neuroretinitis and anterior uveitis following ipilimumab treatment for metastatic melanoma
MISIPI study: Melanoma ImmunoScore evaluation in patients treated with IPIlimumab
Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab
Large granular lymphocytosis with severe neutropenia following ipilimumab therapy for metastatic melanoma
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian ipilimumab expanded access programme (EAP)
Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy
A Dramatic Response to Second-Line Nivolumab and Ipilimumab in BRAF-V600-Mutated Metastatic Melanoma
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
Ipilimumab in patients with melanoma and autoimmune disease
Acute visual loss after ipilimumab treatment for metastatic melanoma
Biomarkers on melanoma patient T Cells associated with ipilimumab treatment
Bilateral neuroretinitis and anterior uveitis following ipilimumab treatment for metastatic melanoma
MISIPI study: Melanoma ImmunoScore evaluation in patients treated with IPIlimumab
Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab
Large granular lymphocytosis with severe neutropenia following ipilimumab therapy for metastatic melanoma
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian ipilimumab expanded access programme (EAP)